Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Income Before Tax

Profit after all operating and non-operating items but before income tax.

Amarin Corporation plcNASDAQ: AMRN

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$12.3M, compared with -$13.63M a year earlier. Trailing-twelve-month income before tax was -$34.72M.

Context

  • Income before tax amounted to 16.9% of revenue in FY2025, down 16.9 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$12.3M or moves back toward the trailing-twelve-month quarterly average of -$8.68M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.3M-1345.9% QoQ
Last fiscal yearDec 2025
-$36.05M+53.3% YoY
LTMMar 2026
-$34.72M+57.8% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.8%——
1 year+53.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(36.05M) USD
Year-over-year change
+53.3%

Income Before Tax vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +57.8% is the highest of 10, against a peer median of -17.6%.
  • Income before tax amounts to 16.2% of revenue for AMRN, versus a peer median of 6088.3%.
AMRN Competitors
Income Before Tax for AMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026-$34.72M USD+57.8%—16.2%
ACIUAC Immune S.A.LTM Mar 2026-CHF 66.22M CHF-27.2%—1788.8%
ENGNenGene Holdings Inc.LTM Apr 2026-$66.65M USD+16.3%——
CLLSCellectis S.A.LTM Mar 2026-$69.45M USD-15.2%—102.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$74.31M USD-17.6%——
SLNSilence Therapeutics plcLTM Mar 2026-$85.16M USD——9241.5%
ALTAltimmune, Inc.LTM Mar 2026-$91.08M USD-0.2%—253002.8%
KRROKorro Bio, Inc.LTM Mar 2026-$112.77M USD-29.2%—2935.1%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$166.01M USD-74.3%——
DBVTDBV Technologies S.A.LTM Mar 2026-$171.4M USD-49.3%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$246.41M USD+26.3%—794858.1%
Peer median (excluding AMRN) —-17.6%—6088.3%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue583.19M369.19M306.91M228.61M213.65M
Cost of Revenue121.33M126.71M141.37M147.23M92.78M
Gross Profit461.86M242.48M165.54M81.38M120.87M
Gross Margin79.2%65.7%53.9%35.6%56.6%
Research & Development29.31M30.41M22.22M20.87M19.81M
Selling, General & Admin408.33M304.42M199.94M152.31M115M
Operating Expenses451.36M348.35M222.16M173.18M134.81M
Depreciation & Amortization2.86M3.1M2.97M3.01M3.03M
EBITDA14.28M(100.69M)(50.7M)(74.18M)(33.01M)
EBITDA Margin2.4%-27.3%-16.5%-32.4%-15.5%
Operating Income10.5M(105.87M)(56.62M)(91.8M)(13.94M)
Operating Margin1.8%-28.7%-18.4%-40.2%-6.5%
Interest Income1.22M2.82M11.86M13.4M10.85M
Interest Expense129K15K8K7K7K
Other Income / Expenses789K2.06M2.95M14.6M(22.11M)
Income Before Tax11.29M(103.81M)(53.67M)(77.2M)(36.05M)
Pre-Tax Margin1.9%-28.1%-17.5%-33.8%-16.9%
Income Tax Expense3.56M2M5.44M4.98M2.75M
Net Income7.73M(105.8M)(59.11M)(82.18M)(38.8M)
Net Margin1.3%-28.7%-19.3%-35.9%-18.2%
EPS (Basic)0.39(5.20)(3.00)(4.00)(1.80)
EPS (Diluted)0.38(5.20)(3.00)(4.00)(1.80)
Weighted Avg Shares19.8M20.06M19.7M20.55M20.75M
Weighted Avg Shares (Diluted)20.12M20.06M20.38M20.55M20.75M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.